Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor
Findings from this study provided real-world evidence of an association between pexidartinib initialization and symptom improvements among patients with symptomatic TGCTs from the patients' and clinicians' perspective.
Authors
- Xin Ye (ORCID: https://orcid.org/0000-0002-5929-3798)
- Kristen M. Tecson (ORCID: https://orcid.org/0000-0002-6732-8698)
- William Tap
- Irene Pan
- Dong Dai (ORCID: https://orcid.org/0000-0002-0231-1422)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Daiichi Sankyo (Germany) (DE)
- United BioSource Corporation (United Kingdom) (GB)
- Daiichi-Sankyo (South Korea) (KR)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1080/14796694.2025.2527586
- Primary Topic
- Musculoskeletal synovial abnormalities and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00